Dingell Aims to Boost FDA Funding - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dingell Aims to Boost FDA Funding


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (Nov. 13)—Rep. John Dingell (D-MI) plans to introduce the Food and Drug Globalization Act discussion draft as a bill early next year. Chairman of the House Energy and Commerce Committee, Dingell has been active in this issue for some time, introducing the discussion draft last spring and a revised version in July. Among other things, the Act would enhance FDA's authority and increase funds for its inspections and compliance programs.

“We need to ensure the safety of our food and drug supply in a global economy,” he said in a statement issued to the Democratic caucus on Nov. 6, 2008. “Already, I’ve released draft legislation to strengthen and adequately fund FDA, thereby improving the safety of food, drugs, medical devices, and cosmetics. Work on the Food and Drug Administration Globalization Act continues. I will introduce this bill early next year and intend to move it through the Committee with the utmost speed.”

Dingell’s statement was part of a longer letter to the Democratic caucus that focused on his desire to serve another term as chairman of the House Energy and Commerce Committee. Rep. Henry Waxman (D-CA) is challenging the chairmanship, which will be decided when the 111th Congressional session begins in January 2009.

Dingell also has been active in the area of drug import safety, sponsoring H.R. 3610, the Food and Drug Import Safety Act of 2007. This Act would create a user fee on imported drug and food shipments. Funds generated by the fee would be used to hire additional personnel to perform inspections worldwide to increase the analysis of drug and food imports. Funds would also be used to test import samples and research new testing techniques. See PharmTech’s coverage of this issue.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here